“…Although this variant is associated with both agonistic and antagonistic effects in vitro (Small, Brown, Forbes, and Liggett, 2001), researchers have speculated that it results in greater norepinephrine availability during emotional events (Rasch, Spalek, Buholzer, Luechinger, Boesiger, Papassotiropoulos, and de Quervain, 2009), a physiological condition associated with enhanced learning and memory (McGaugh, 2004). In healthy individuals, carriers of the ADRA2B deletion variant exhibit enhanced perception and memory of emotional stimuli (de Quervain, Kolassa, Ertl, Onyut, Neuner, Elbert, and Papassotiropoulos, 2007; Mammarella, Fairfield, Di Domenico, D’Onofrio, Stuppia, and Gatta, 2016; Todd, Muller, Lee, Robertson, Eaton, Freeman, Palombo, Levine, and Anderson, 2013), as well as greater amygdala activity during the encoding of emotionally arousing information (Cousijn, Rijpkema, Qin, van Marle, Franke, Hermans, van Wingen, and Fernandez, 2010; Rasch et al, 2009), which, in some cases, has been selectively reported following stress (Li, Weerda, Milde, Wolf, and Thiel, 2015). Although there are no studies showing a greater incidence of PTSD in deletion carriers, research has shown that the deletion variant is associated with greater intrusiveness of traumatic memories in Rwandan Civil War survivors (de Quervain et al, 2007), and the significant amount of work revealing exaggerated noradrenergic activity in PTSD (Skelton et al, 2012; Strawn and Geracioti, 2008; Zoladz and Diamond, 2013) presents the possibility of a connection between the ADRA2B deletion variant and PTSD-like phenotypes that warrants further investigation.…”